PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 107 filers reported holding PMV PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $914,424 | -25.4% | 148,929 | -24.0% | 0.00% | – |
| Q2 2023 | $1,226,440 | -72.4% | 195,917 | -79.0% | 0.00% | – |
| Q1 2023 | $4,444,199 | -49.7% | 931,698 | -8.2% | 0.00% | -100.0% |
| Q4 2022 | $8,832,380 | +56.5% | 1,015,216 | +114.0% | 0.00% | 0.0% |
| Q3 2022 | $5,645,000 | -8.6% | 474,371 | +9.5% | 0.00% | 0.0% |
| Q2 2022 | $6,176,000 | +15.5% | 433,326 | +68.7% | 0.00% | 0.0% |
| Q1 2022 | $5,347,000 | +213.4% | 256,837 | +247.9% | 0.00% | – |
| Q4 2021 | $1,706,000 | +112.2% | 73,819 | +173.7% | 0.00% | – |
| Q3 2021 | $804,000 | -41.2% | 26,969 | -32.6% | 0.00% | – |
| Q2 2021 | $1,367,000 | +7.3% | 40,019 | +3.3% | 0.00% | – |
| Q1 2021 | $1,274,000 | +366.7% | 38,746 | +771.5% | 0.00% | – |
| Q4 2020 | $273,000 | +2381.8% | 4,446 | +1382.0% | 0.00% | – |
| Q3 2020 | $11,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |